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The association of carotid plaque inflammation
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Objective: Inflammation and infection have been implicated in the pathogenesis of carotid artery atherosclerosis, but their
role in cerebrovascular disease symptomatology is not so well defined. We hypothesized that carotid disease symptom-
atology was associated with specific serologic markers of inflammation and Chlamydia pneumoniae infection and the
presence of the pathogen and concentration of tumor necrosis factor- (TNF-) on the atheroma.
Methods: In 2004, 78 patients underwent carotid endarterectomy in our department, 46 of whom were symptomatic
(group A) and 32 were asymptomatic (group B). A detailed medical history, the presence of atherosclerosis risk factors,
ankle-brachial index and boxy mass index were recorded. We measured preoperatively the levels of C-reactive protein,
fibrinogen, TNF-, and the titers of immunoglobulin (Ig) A and IgG antibodies against C pneumoniae in the serum.
Finally, the atherosclerotic plaques of all patients were immunohistochemically examined for the presence of C
pneumoniae and their TNF- concentration was determined.
Results: Isolation of the pathogen on the atheromatous lesion was statistically correlated with several risk factors and some
of the variables that were tested. After testing independence of association, using the multiple regression analysis, only
male gender (P .024), hypertension (P .008), hypercholesterolemia (P .001), and TNF- plaque values (P .008)
remained significantly associated. Hypertension, serum levels of fibrinogen and anti-C pneumoniae immunoglobulin A,
detection of C. pneumoniae on the plaque, and plaque TNF- values were significantly correlated with carotid disease
symptomatology. After multiple analyses, only the presence of the pathogen on the lesion (P  .008) and atheroma
TNF- levels (P  .025) remained significantly associated with cerebrovascular events.
Conclusions: It seems that hypertensive hypercholesterolemic men are more likely to have C. pneumoniae infected carotid
plaques and that these plaques have higher TNF- concentrations. Cerebrovascular disease symptomatology is strongly
correlated with both C. pneumoniae infection and TNF- concentration of the atheroma. (J Vasc Surg 2006;44:
1198-1204.)Inflammation is now recognized as an integral part of
atherogenesis.1 This low-grade chronic inflammatory pro-
cess may result from an excessive response to various in-
flammatory stimuli, including infection. The association of
several infectious agents with cardiovascular disease has
been investigated in the last two decades.2 The pathogen
most strongly associated with atherosclerosis so far is Chla-
mydia peumoniae.3
Many different kinds of studies have attempted to link
this obligate intracellular gram-negative bacterium to the
pathogenetic process of atherosclerotic disease. Seroepide-
miologic and histopathologic studies, animal models of
experimental atherosclerosis and chlamydial infection, and
antibiotic intervention studies have all been trying to elu-
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1198cidate the role that this microorganism could play in
cardiovascular disease. It is quite interesting to explore
whether C pneumoniae is involved in the initiation, pro-
gression, or complications of the atheromatous lesion. C
pneumoniae serology4 and plaque colonization5 have been
correlated with carotid atherosclerosis. Chronic infection
from C pneumoniae has also been associated with lesion
development and the cerebrovascular symptomatology.6
This sustained dormant infection could be the cause of
the increased levels of several inflammatory markers, in-
cluding C-reactive protein (CRP) and fibrinogen. These
markers seem to be equally important for, and indicative of,
the clinical manifestations of carotid artery disease. They
are probably involved in plaque evolution and stability.7
Cytokines seem to have a central role in atheroma develop-
ment and rupture.8 Tumor necrosis factor- (TNF-), in
particular, has been shown to be intimately involved in the
atherosclerotic process. It has been known to contribute to
the recruitment of inflammatory cells, and vascular smooth
muscle and endothelial cells apoptosis, which could lead to
cap thinning and plaque destabilization.9 TNF- receptor
levels have been linked to carotid atherosclerosis.10
C pneumoniae induces TNF- production in infected
macrophages, monocytes, smooth muscle or endothelial
cells in vitro, and this synergy may be very important for
lesion stability.11 To our knowledge, TNF- lesion con-
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C pneumoniae detection on the atheroma or with stroke
and transient ischemic attacks. The aim of our study was to
investigate the relationship of serum and carotid plaque
markers of inflammation and C pneumoniae infection with
cerebrovascular symptomatology.
METHODS
Between January 1 and December 2004, 86 consecu-
tive patients underwent carotid endarterectomy in the Vas-
cular Surgery Unit of the Second Dept of Propedeutic
Surgery, Laikon Hospital, Athens University. Three pa-
tients failed to provide informed consent and five were
excluded according to the exclusion criteria. The study thus
included 78 patients: 46 were symptomatic (group A) and
32 were asymptomatic (group B). The study was approved
by the hospital Ethics Committee, and informed consent
was obtained from all participants.
Indication for surgery was a symptomatic carotid ste-
nosis50% or an asymptomatic carotid stenosis70%. All
patients had brain computed tomography (CT) scans and
carotid duplex ultrasound scans preoperatively. Symptom-
atic disease was defined as the presence of clinical manifes-
tations of transient ischemic attack (TIA) or stroke in the
last 6 months, irrespective of the brain imaging findings. Of
the symptomatic patients, 20 had a recent history of TIA,
and 26 had had a stroke. Exclusion criteria for both groups
were the presence of chronic or active inflammatory or
infectious disease, malignancy; systematic administration
(3 days) of anti-inflammatory drugs, antibiotics, or cor-
ticosteroids; and pathologic white blood cell count and
erythrocyte sedimentation rate value.
At entry into the study, a complete medical history was
taken and risk factors were recorded, including age, gender,
coronary artery disease (angina pectoris, myocardial infarc-
tion, coronary artery by-pass grafting, percutaneous translu-
minal coronary angioplasty), diabetes mellitus (controlled
with diet, oral hypoglycemic agents or insulin; fasting glucose
level 7 mmol/L), hypercholesterolemia (on statin therapy,
total cholesterol5.2 mmol/L), hypertension (on antihy-
pertensive treatment, blood pressure160mmHg systolic
or 95 mm Hg diastolic), and smoking history (current or
past). The demographic characteristics of the study patients
are summarized in Table I.
Height and weight were measured and the body mass
index (BMI) of obesity was calculated in all patients. Base-
line assessment included measurement of ankle-brachial
systolic pressure index (ABI). Systemic blood pressure in
both arms and ankles was measured using a hand held
8-MHz Doppler device (Huntleigh Doppler, Cardiff,
Wales) and a standard mercury sphygmomanometer.
All our patients, both symptomatic and asymptomatic,
were taking low-dose aspirin prophylaxis. Aspirin treatment
was interrupted 1 week before the expected day of surgery.
Upon admission, venous blood samples were obtained for
the determination of CRP, fibrinogen, and TNF- levels in
the serum as well as for the measurement of immunoglob-
ulin (Ig) A and IgG anti-C pneumoniae (CP) titers and thesamples were immediately stored at –70°C and analyzed at
the end of the study.
CRP levels were measured by the photometric-
turbidimetric test for the quantitative determination of
human high-sensitivity CRP in serum and plasma (Human,
Wiesbaden, Germany). Positive was considered a value
0.5 mg/dL. Fibrinogen was measured using the photo-
metric method. TNF- levels were calculated by the Titer-
zyme Enzyme Immunometric Assay of human TNF- (As-
say Designs, Inc, Ann Arbor, Mich). The antibodies used
do not show significant cross-reactivity with other known
cytokines. All samples were assayed in duplicate by techni-
cians blind to the clinical information. The IgA and IgG
anti-CP titers were determined by the quantitative enzyme-
linked immunosorbent assay (ELISA) technique (Immu-
nolisa, Orgenics, Israel). They were measured in enzyme
immunounits (IEU), and positivity was appointed to values
5 EIU/mL.
Finally, the carotid plaque surgical specimens were
collected immediately after surgery and divided in half
longitudinally. One half was sliced and four plates for each
patient were kept at –70°C until the time of the assay. The
presence of C pneumoniae on the specimen was detected
with immunohistochemistry (IHC) techniques, using the
alkaline phosphatase staining method of DynaChrome
(ThermoShandon, Pittsburgh, Pa) and the monoclonal
antibody to C pneumoniae (Biogenex, San Ramon, Calif).
The technique was considered positive when cell groups
and not isolated cells were stained positively. The other half
was homogenized in an ice-cold homogenization buffer.
The homogenates were centrifuged and the supernatants
were stored at –70°C until analysis. Tissue content of
TNF- was determined by the use of an ELISA kit (Bio-
source International, Inc, Camarillo, Calif). The minimum
detectable dose of TNF- is 3.0 pg/mL.
In the statistical analysis, continuous variables are ex-
pressed as mean  SD, and categoric variables are pre-
sented as percentages. Comparisons of continuous vari-
ables among the groups were made using the Pearson
Table I. Patient demographics and clinical characteristics
Variables
Group A
(n  46)
Group B
(n  32) P
Age, years 70.1  7.5 68.1  3.2 0.15
Gender: men 69.6 (32) 75.0 (24) 0.80
BMI (kg/m2) 27.7  2.8 27.5  2.7 0.77
ABI 0.83  0.17 0.89  0.16 0.12
Hypertension 82.6 (38) 53.1 (17) 0.006*
Coronary artery disease 37.0 (17) 56.3 (18) 0.11
Diabetes mellitus 52.2 (24) 37.5 (12) 0.25
Hypercholesterolemia 56.5 (26) 62.5 (20) 0.65
Statin therapy 43.5 (20) 53.1 (17) 0.71
Smoking 56.5 (26) 65.6 (21) 0.48
Group A, Symptomatic patients; Group B, asymptomatic patients; BMI,
body mass index; ABI, ankle-brachial index.
Values are mean  SD or percentages and (numbers).
*Significant.parametric or the Spearman nonparametric test, as appro-
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appropriate, for pair-wise comparisons between the groups
of interest. Associations between two categoric variables
were tested by the 2 test or the Fisher’s exact test, as
appropriate. After determining univariate associations,
multivariate analysis (multiple linear regression analysis)
was used to determine independence of associations. All
tests were two-tailed and P  .05 was considered signifi-
cant. All the analyses were done with the SPSS 9.0 statistical
software (SPSS Inc, Chicago, Ill).
RESULTS
As can be seen in Table I, there were no statistically
significant differences in most of the traditional cardiovas-
cular risk factors of coronary artery disease, diabetes melli-
tus, hypercholesterolemia, smoking, age, gender, BMI,
ABI, or statin therapy between the symptomatic and the
asymptomatic patients. Only hypertension was significantly
more common in group A compared with group B patients
(P  .006).
Serology revealed no difference between the two groups
in CRP and TNF- values or in the levels of anti-CP IgG
(Table II). Fibrinogen serum values were significantly
higher in the symptomatic group (P  .044). The mean
anti-CP IgA levels in group A patients were almost double
those in group B (P  .006). One in four symptomatic
patients had anti-CP IgA values8.2 EIU/mL, whereas in
asymptomatic patients, the highest quartile started at 7.0
EIU/mL. IgA seropositivity, according to the standards set
by the manufacturer (5EIU/mL), was also significantly
correlated with the symptomatic form of the disease (P 
.001). Four of five subjects were positive in group A. Only
Table II. Inflammatory serum markers, Chlamydia
pneumoniae serology, immunohistochemical detection of
the pathogen on the atheroma, and tumor necrosis
factor- plaque values in symptomatic and asymptomatic
patients
Variables
Group A
(n  46)
Group B
(n  32) P
CRP (mg/dL) 1.93  3.36 1.79  2.75 0.83
Fibrinogen (mg/dL) 240.1  71.7 206.8  68.3 0.044*
TNF- (pg/mL) 21.8  13.5 17.1  6.0 0.070
Anti-CP†
IgA (EIU/mL) 11.06  8.6 5.53  8.32 0.006*
IgG (EIU/mL) 36.2  29.0 28.6  24.2 0.23
IgA 78.3 (36) 31.3 (10) 0.001*
IgG 84.8 (39) 87.5 (28) 1.00
IHC 80.4 (37) 25.0 (8) 0.001*
Plaque TNF-
(pg/mL)
227.7  130.9 18.7  16.5 0.001*
Group A, Symptomatic patients; Group B, asymptomatic patients; CRP,
C-reactive protein; TNF, tumor necrosis factor; CP, Chlamydia pneu-
moniae; IHC, immunohistochemistry.
Values are mean  SD or percentages (numbers).
*Significant value.
†Anti-CP IgA when 5 EIU/mL; Anti-CP IgG when 5 EIU/mL.a third of the second group was positive (Fig 1). Forsymptomatic patients with carotid artery disease, the odds
ratio of being IgA seropositive was 9.2 (95% confidence
interval [CI], 3.2 to 26.1) times greater than that of being
seronegative. This is quite a significant odds ratio in favor of
IgA seropositivity being a risk factor of cerebrovascular
events, since the lower confidence limit is well above 1.
Immunohistochemical plaque positivity was far more
common in the first group (P  .001). Almost four of five
symptomatic atheromas stained positive for the presence of
C pneumoniae, whereas only one quarter of the group B
patients’ plaques displayed the characteristic positive stain
(Fig 2). Mean TNF- symptomatic lesion level was 10
times higher than the corresponding asymptomatic lesion
value (P  .001). Fig 3 clearly shows the significant differ-
ence in plaque TNF- concentrations between symptom-
atic and asymptomatic patients. It is also evident that
symptomatic seropositive subjects for anti-CP IgA have
higher plaque TNF- levels than those who are symptom-
atic seronegative, but this association was just over the limit
of statistical significance (P  .056). TNF- serum values
were strongly associated with the concentration of TNF-
on the atheroma (P  .001). The five variables that were
significantly correlated with carotid symptomatology were
entered into a multivariate analysis model (multiple linear
regression) with symptomatic disease as the dependent
variable. Table III shows that the presence of C pneu-
moniae on the plaque and lesion TNF- values remained
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Fig 1. Anti-Chlamydia pneumoniae (Cp) immunoglobulin A (IgA)
seropositivity in patients with symptomatic and asymptomatic ca-
rotid artery disease.
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Fig 2. Chlamydia pneumoniae was detected much more often in
the carotid plaques of symptomatic patients. IHC, Immunohisto-
chemistry.risk factors for cerebrovascular symptomatology.
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the atheroma was found to have many significant associa-
tions (Fig 4). Men’s plaques were found infected in 80%
of the cases, while only half of women’s lesions stained
positive for C pneumoniae (P  .041). Among the tradi-
tional cardiovascular risk factors, hypertension (P  .001)
hypercholesterolemia (P .039), and smoking (P .005)
were associated with IHC atheroma positivity. Only 10% of
IHC-positive patients were normotensive, and about 45%
of IHC-negative subjects were hypertensive. Almost three
of four hypercholesterolemic patients, but less than half of
normocholesterolemic ones had C pneumoniae infected
plaques. Among smokers, the lesions of 75% stained
positively, whereas in the nonsmoking population, this was
the case in 45%. IHC-positive subjects were also older,
with higher BMI and higher TNF- serum values. Mean
anti-CP IgA serum level (Fig 5) was almost double in patients
with infected plaques comparedwith IHC-negative ones (P
.001). Finally, TNF- atheroma concentration was many
times higher in patients with C pneumoniae plaque infection
compared with those that stained negatively for the patho-
gen (P  .001). All the independent variables associated
Fig 3. Tumor necrosis factor- (TNF-) plaque levels were sig-
nificantly higher in symptomatic patients compared with asymp-
tomatic patients. Especially in symptomatic anti-Chlamydia pneu-
moniae (Cp) immunoglobulin A (IgA) seropositive subjects, the
levels of TNF- on the atheroma were higher than in seronegative
subjects, but the difference was not statistically significant (P 
.056). Range bars indicate median and interquartile range and
whiskers indicate outliers.
Table III. Multiple linear regression analysis*
Standardized
coefficient (B) SE (SEB) t P
Hypertension .128 .118 1.182 .241
Fibrinogen .150 .001 1.622 .109
Anti-CP IgA .086 .006 .868 .388
IHC .317 .115 2.744 .008†
Plaque TNF- .248 .001 2.297 .025†
SE, Standard error; IgA, immunoglobulin A; TNF, tumor necrosis factor;
CP, Chlamydia pneumoniae; IHC, Immunohistochemistry.
*Symptomatic carotid disease is the dependent variable and hypertension,
fibrinogen and anti-CP IgA serum values, IHC plaque positivity, and TNF-
plaque levels are the independent variables.
†Significant.with IHC were introduced in the multivariate regressionanalysis. Only male gender (P  .024), hypertension (P 
.008), hypercholesterolemia (P  .001), and high TNF-
plaque values (P  .008) retained their significance.
DISCUSSION
Chronic inflammation and infection seem to play an
important role in the development of atherosclerotic le-
sions. Melnick et al12 were the first to associate C pneu-
moniae seropositivity with carotid atherosclerosis. C pneu-
moniae seropositivity was found to have a significant
association with acute stroke and TIAs.13 Elevated anti-CP
IgA and IgG antibodies were associated with an increase of
intima–media thickness or progression of carotid steno-
sis.14 A recent study has shown an increased aortic intima–
media thickness in healthy children with persistent C pneu-
moniae seropositivity.15 In a large prospective study,
C pneumoniae IgG seropositivity seems to influence signif-
icantly the future occurrence of cerebrovascular events.7
Other studies have failed to show the association of
C pneumoniae serology with cerebrovascular disease and
symptomatology.16,17 In our study, IgA seropositivity was
associated with the symptomatic form of carotid disease.
After multiple analyses, the association was no longer sta-
tistically significant.
Microimmunofluorescence (MIF) is the established se-
rologic method for diagnosing C pneumoniae infection.
We used ELISA, which has been shown to have an overall
correlation of about 90% with the MIF test in terms of
sensitivity and specificity and is considered less subjective
and less operator dependent.18 In a significant comparative
study, there was a good concordance of MIF and ELISA
results.19 IgA antibodies against C pneumoniae have shown
little correlation with the detection of the microorganism in
atherosclerotic plaques.5 Others, supporting our findings,
still consider Chlamydia serology a marker of atheroma
infection.20
According to the Centers for Disease Control and
Prevention USA guidelines,21 IHC, polymerase chain re-
action (PCR), and culture are the three methods approved
for C pneumoniae detection on the lesion. The validity of
our IHC method had been recently questioned,22 but a
comparative study that we have traced in the literature
shows a good correlation between PCR and IHC results.23
C pneumoniae was detected in 57.7% of the plaques,
which is well within similar figures in the literature, al-
though some using PCR have failed to detect the pathogen
in carotid atheromas.24 Plaque infection was much more
common among men, which was probably due to their
overwhelming percentage of smokers. It is generally ac-
cepted that smoking favors the development of respiratory
infections, including chlamydial ones.25 Hypertension and
hypercholesterolemia have also been associated with
C pneumoniae detection on the atheroma. From the liter-
ature, hypertension has been linked toC pneumoniae serol-
ogy,26 and hyperlipidemia is considered a co-risk factor of
the pathogen for atherosclerosis.27
The association of plaque infection and plaque TNF-
concentration is extremely important. TNF- is produced
roma
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plaque when infected by C pneumoniae.28 It has been
correlated with the serologic diagnosis of C pneumoniae
infection,29 but it has not yet been associated with plaque
infection. When monocytes are exposed to the action of
specific antichlamydial antibiotics (eg, the quinolones) the
levels of production of TNF- are significantly reduced.30
Others have found that specifically in carotid lesions, chla-
mydial lipopolysaccharide increases cytokine expression,
including a 50-fold increase in TNF- expression.31
IgA seropositivity and C pneumoniae PCR-positive
peripheral blood mononuclear cells have already been
linked to cerebrovascular symptomatology.6,32 Others
have failed to associate plaque detection of the pathogen
with symptomatic stenosis.33 In another arterial bed, isola-
tion of the microorganism in femoral plaques has been
correlated with the severity of claudication.34 Experimental
data show that carotid C pneumoniae infection leads to
progression of atherosclerotic lesions with a more vulnera-
Fig 4. Immunohistochemistry of plaque specimens. A
detection ofChlamydia pneumoniae by use of a specific m
and alkaline phosphatase (magnification 400), B, Athe
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Fig 5. Immunoglobulin A (IgA) serum values in patients with
Chlamydia pneumoniae (Cp) infected (IHC) and non-infected
(IHC–) plaques (P  .001, Mann-Whitney test). IHC, Immuno-
histochemistry. Range bars indicatemedian and interquartile range
and whiskers indicate outliers.ble morphology in LDLr–/– mice.35Although the large antibiotic intervention trials in cor-
onary patients had no positive effect, antibiotic treatment
of C pneumoniae seropositive patients resulted in reduced
progression of early carotid atherosclerosis.36 The issue is
still unsettled, but published reports seem to support the
association ofC pneumoniae plaque infection with cerebro-
vascular symptomatology.
TNF- atheroma concentrations have never before, to
our knowledge, been related to stroke and TIAs. The only
hint of information we have had so far is that in symptom-
atic patients with carotid stenosis of 70%, the levels of
messenger RNA for TNF- are increased in the plaque
area.37 TNF-, probably through its apoptotic properties,
may be responsible for plaque rupture.38 It also contributes
to the acceleration of atherosclerosis by C pneumoniae in
mice.39 C pneumoniae in synergy with TNF- stimulates
matrix metalloproteinase production, which could be very
important for plaque stability.40 Chlamydial heat shock
protein 60 induces TNF- and matrix metalloproteinase
production by macrophages.41
A significant limitation of our study is that C pneu-
moniae detection and TNF- concentration of the lesion
are postoperative findings. Therefore, either the patient is
already symptomatic or the probable carotid embolic
source has been treated, which makes these findings of
rather theoretic clinical utility. However, IgA seropositivity
could prove clinically useful.
CONCLUSION
Our data suggest that cerebrovascular symptomatology
is associated both with plaque inflammation, expressed by
plaque TNF- values, and plaque C pneumoniae infection.
Plaque TNF- production is strongly related to the pres-
ence of the pathogen. Serum TNF- and anti-CP IgA
levels, which have been correlated with atheroma TNF-
concentration and C pneumoniae infection, respectively,
aracteristically (red fast stain) stained plaque for the
lonal antibody forChlamydia, an avidin-biotin complex,
negative for C pneumoniae (magnification 200)., Ch
onoccould in the future serve as serologic predictors of symp-
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ings. Clinical and therapeutic implications of these results
remain to be evaluated.
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